文献速递肿瘤 PET/CT

Nectin-4靶向PET显像剂68Ga-FZ-NR-1在三阴性乳腺癌中的先导研究:从基础到首次人体试验

Pilot Study of Nectin-4-Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
PubMed 文献 · J Nucl Med · 2025-03-03

本研究合成并评价了三种Nectin-4靶向放射性示踪剂,其中68Ga-FZ-NR-1在体外和荷瘤模型中靶向效能最高,随后在9例三阴性乳腺癌患者中开展首次人体试验,68Ga-FZ-NR-1 PET/CT可有效识别肿瘤病灶,且阳性病灶与免疫组化证实的Nectin-4高表达区域相对应。

要点

  • 68Ga-FZ-NR-1在体外和荷瘤模型中靶向Nectin-4效能高于68Ga-FZ-NR-2和68Ga-FZ-NR-3。
  • 68Ga-FZ-NR-1 PET/CT在9例三阴性乳腺癌患者中有效识别肿瘤,并经18F-FDG PET/CT确认。
  • 活检显示68Ga-FZ-NR-1 PET/CT阳性病灶对应Nectin-4高表达区域。

核心结论

  • 临床前研究显示68Ga-FZ-NR-1可识别Nectin-4高表达肿瘤,初步临床研究显示其可有效识别和可视化三阴性乳腺癌患者的Nectin-4表达肿瘤病灶,并经免疫组化确认。

研究设计与样本

  • 先导研究:合成三种Nectin-4靶向放射性示踪剂,在MDA-MB-468(Nectin-4阳性)和MDA-MB-231(Nectin-4阴性)细胞系及荷瘤模型中进行体外和体内评价,筛选后选用68Ga-FZ-NR-1在三阴性乳腺癌患者中开展首次人体试验。

主要发现

  • 三种68Ga标记示踪剂均具有高放射化学纯度、稳定性和对Nectin-4的强亲和力。
  • 体外细胞摄取研究显示示踪剂有效靶向MDA-MB-468细胞中的Nectin-4,其中68Ga-FZ-NR-1靶向效能最高。
  • 在MDA-MB-468荷瘤模型中,68Ga-FZ-NR-1的PET/CT摄取率高于68Ga-FZ-NR-2和68Ga-FZ-NR-3,并表现出良好的药代动力学和安全性特征。
  • 68Ga-FZ-NR-1 PET/CT在9例三阴性乳腺癌患者中有效识别肿瘤,并经18F-FDG PET/CT确认。
  • 肿瘤病灶活检样本显示68Ga-FZ-NR-1 PET/CT识别的阳性病灶对应Nectin-4高表达区域。

关键数值与推荐

  • 68Ga-FZ-NR-1在MDA-MB-468荷瘤模型中的摄取率高于68Ga-FZ-NR-2和68Ga-FZ-NR-3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nectin cell adhesion molecule 4 (Nectin-4) is an emerging biomarker for cancer diagnosis and therapy. We developed a Nectin-4-targeted 68Ga-DOTA-Sar10-Nectin-4 (68Ga-FZ-NR-1) PET/CT radiotracer for detecting Nectin-4 expression in a tumor model and in triple-negative breast cancer (TNBC) patients. Methods: A series of Nectin-4-targeted radiotracers-68Ga-FZ-NR-1, 68Ga-DOTA-polyethylene glycol 5-Nectin-4 (68Ga-FZ-NR-2), and 68Ga-DOTA-polyethylene glycol 10-Nectin-4 (68Ga-FZ-NR-3)-were synthesized, and their targeting ability and specificity were evaluated in vitro and in vivo. In vitro experiments were performed in the MDA-MB-468 (Nectin-4-positive) and MDA-MB-231 (Nectin-4-negative) cell lines. PET/CT imaging in tumor models was performed to assess the Nectin-4-targeting ability of the radiotracers. After preclinical experiments and screening, the 68Ga-FZ-NR-1 radiotracer was selected for safety and efficacy evaluation in a first-in-human trial in TNBC patients. Positive lesions were biopsied and analyzed by immunohistochemistry to determine Nectin-4 expression levels. Results: The 3 68Ga-labeled radiotracers exhibited high radiochemical purity, stability, and strong affinity for Nectin-4. In vitro cell uptake studies showed that the radiotracers effectively targeted Nectin-4 in MDA-MB-468 cells, and 68Ga-FZ-NR-1 showed the highest targeting efficacy. In the MDA-MB-468 tumor model, PET/CT imaging showed that 68Ga-FZ-NR-1 was taken up at higher rates than 68Ga-FZ-NR-2 and 68Ga-FZ-NR-3, and it exhibited favorable pharmacokinetics and safety profiles. 68Ga-FZ-NR-1 was thus selected for subsequent clinical trials. 68Ga-FZ-NR-1 PET/CT effectively identified tumors in 9 patients with TNBC, which was confirmed by 18F-FDG PET/CT. Biopsy samples of the tumor lesions revealed that the positive lesions identified by 68Ga-FZ-NR-1 PET/CT corresponded to areas of high Nectin-4 expression. Conclusion: A series of Nectin-4-targeted radiotracers (68Ga-FZ-NR-1, 68Ga-FZ-NR-2, and 68Ga-FZ-NR-3) was developed and evaluated. Preclinical studies demonstrated that 68Ga-FZ-NR-1 can identify tumors with high Nectin-4 expression. In a preliminary clinical study, 68Ga-FZ-NR-1 was used to effectively identify and visualize Nectin-4-expressing tumor lesions in patients with TNBC, which was confirmed by immunohistochemistry. This radiotracer provides a noninvasive approach to the assessment of Nectin-4 and a potential basis for the development of Nectin-4-targeted treatments for TNBC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sun L, Sun Y, Zuo K, et al. Pilot Study of Nectin-4-Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human. J Nucl Med. 2025. PMID: 39947908. doi:10.2967/jnumed.124.269024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。